Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial

Tavakoli-Ardakani, Maria; Mehrpooya, Maryam; Mehdizadeh, Mahshid; Beiraghi, Narges; Hajifathali, Abbas; Kazemi, Mohammad Hossein

doi:10.1038/s41409-019-0623-0

Cited by 18 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The only trial of antidepressant in transplant patients since 2020 comes from Tavakoli and looked at the effect of sertraline in HCT patients with depression. Sertraline was associated with significant reduction of depressive scores on HADS (65% versus placebo 10%, P < 0.0001) and the improvement of depressive symptoms were paralleled by the reduction of IL-6 levels; however, it did not correlate with IL-10 levels [79 ▪ ]. This study further supports the need to understand the relationship between mood and immunity in the transplant population.…”

Section: Therapeutic Interventions For Depressionsupporting

confidence: 59%

Depression in transplantation

Zimbrean¹

2022

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of reviewTo review and summarize the literature published between 1 January 2020 and 30 June 2022, on the prevalence, risk factors and impact of depression in transplant population. Recent findingsDepression is common in transplantation candidates and recipients, with a prevalence up to 85.8% in kidney recipients. Multiple studies have indicated after transplantation depression correlates with increased mortality and with higher healthcare utilization. Social risk factors for posttransplant depression include financial difficulties and unemployment, while less is understood about the biological substrate of depression in this population. There is evidence that dynamic psychotherapy is effective for depression in organ transplant recipients, while cognitive behavioral therapy or supportive therapy did not lead to improvement of depression in transplant recipients. For living organ donors, the rates of depression are similar to the general population, with financial factors and the clinical status of the recipient playing a significant role. SummaryDepression is a common finding in transplant population. More research is needed to understand the biological substrate and risk factors and to develop effective treatment interventions.

show abstract

Section: Therapeutic Interventions For Depressionsupporting

confidence: 59%

Depression in transplantation

Zimbrean¹

2022

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

show abstract

“…A number of drugs, such as selegiline, duloxetine, citalopram, fluvoxamine, and mirtazapine, also have a beneficial effect in reducing negative symptoms. Selective serotonin reuptake inhibitors (SSRIs) reduce IL-6 and CRP levels (58).…”

Section: Malmberg Et Al (60) Reviewmentioning

confidence: 99%

“…Minocycline is a second-generation tetracycline that works by reducing proinflammatory cytokines, and its effectiveness is emphasized, especially in the early and stable stages of the disease (58). Table 6 summarizes the most important findings related to pharmacotherapy for schizophrenia, including postadolescent schizophrenia.…”

Section: Malmberg Et Al (60) Reviewmentioning

confidence: 99%

Crossroad between current knowledge and new perspective of diagnostic and therapy of late-onset schizophrenia and very late-onset schizophrenia-like psychosis: An update

Stępień-Wyrobiec

Nowak²,

Wyrobiec³

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

Schizophrenia is a chronic, highly individualized disease with many symptoms that can occur with varying severity in different patients. Schizophrenia affects 1% of the population, but occurs in almost 20% of patients after 40 years of age. It should be noted that the next peak in the incidence of schizophrenia occurs at the age of 60 years, affects mostly females, and is closely associated with a high risk of developing memory disorders. Therefore, postadolescent schizophrenia includes two distinct groups of patients: those whose symptoms onset at the age of 45 or 60. The purposes of this literature review were as follows: (1) synthetically characterize the clinical manifestations of schizophrenia; (2) discuss difficulties in the diagnosis of schizophrenia, especially in patients over 40 years of age; (3) discuss the clinical utility of different classes of marker in diagnostic and differentiating schizophrenia from neurodegenerative diseases in elderly people; (4) discuss therapeutic options for schizophrenia, pharmacotherapy, and psychotherapy, emphasizing the role of caregivers of people with psychosis in therapy, in preadolescence and postadolescence schizophrenia. We have tried to primarily discuss the findings of original articles from the last 10 years with an indication of their clinical implications with the issues discussed in the various subsections. Moreover, despite many years of research, no specific, precise algorithm has been developed that can be used in clinical practice during the diagnosis of schizophrenia. For this reason, the diagnosis of schizophrenia is primarily based on an interview with the patient and his family, as well as on the experience of a psychiatrist. It also seems that schizophrenia treatment should be carried out holistically, including pharmacotherapy, psychotherapy, and the support of caregivers of patients who have this psychosis, which increases the achievement of therapeutic success. Finally, we must be aware of the difficulties in diagnosing schizophrenia in the elderly and the need to modify pharmacological treatment. Currently, no guidelines have been developed for the differentiation of negative symptoms in elderly patients with schizophrenia from amotivation/avolition/apathy symptoms in elderly patients with neurodegenerative disorders.

show abstract

“…Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a promising treatment in patients with blood disorders. 1 It has been found that successful engraftment is critical in decreasing the relapse risk. Hematopoietic stem cells (HSCs) privilege over residual leukemic cells in the competition for limited spaces of bone marrow niche reduces the risk of disease recurrence.…”

Section: Introductionmentioning

confidence: 99%

The effect of granulocyte colony‐stimulating factor dose and administration interval after allogeneic hematopoietic cell transplantation on early engraftment of neutrophil and platelet

Noorazar

Bonakchi

Sankanian

et al. 2021

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

Background Hematopoietic stem cell transplantation (HSCT) is one of the treatments for hematologic malignancies. Numerous factors affect the HSCT outcome. The purpose of this study was to investigate the effect of post‐HSCT administration of granulocyte colony‐stimulating factor (post‐G‐CSF) on early neutrophil and platelet engraftment in allogeneic HSCT (allo‐HSCT). Material & methods The study was performed on 76 patients diagnosed with AML and ALL. All patients underwent allo‐HSCT at Taleghani stem cell transplantation center, Tehran, Iran, from February 2016 to December 2018. Chemotherapy regimens based on patients' conditions were selected between myeloablative and reduced‐intensity regimens. Results Statistical analysis revealed that the number of administered G‐CSF units after HSCT was a time‐dependent variable. Statistical analysis before day +11 reported that patients who received G‐CSF <14 units had three times better early neutrophil engraftment than those with G‐CSF ≥14 (CI 95%, AHR = 3.03, p:0.002). CD3+ cells count <318.5 × 106/kg was associated with fast platelet engraftment (CI 95%, AHR 2.28, p:0.01). Conclusion In this study, post‐G‐CSF stimulation was associated with early engraftment in a time‐ and dose‐dependent manner. Administration of G‐CSF beyond 14 units resulted in adverse effects on neutrophil early engraftment. It also appeared that with a reduction in CD3+ cell counts, the likelihood of GVHD decreases, and platelet engraftment occurs earlier. Further investigations in the future are required to determine the factors affecting the process of early engraftment.

show abstract

Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial

Cited by 18 publications

References 9 publications

Depression in transplantation

Depression in transplantation

Crossroad between current knowledge and new perspective of diagnostic and therapy of late-onset schizophrenia and very late-onset schizophrenia-like psychosis: An update

The effect of granulocyte colony‐stimulating factor dose and administration interval after allogeneic hematopoietic cell transplantation on early engraftment of neutrophil and platelet

Contact Info

Product

Resources

About